The clinical outcome of allogeneic hematopoietic stem cell transplantation (SCT) is strongly influenced from the complications arising during the post-transplant immune restoration and has been well studied and described. However, the metabolic status of the recipient pre-transplant also has the potential to influence this outcome and has never been studied before and has the potential to enable risk stratification with respect to the development of transplant associated complications such as graft vs. host disease (GVHD). In order to better understand this aspect of transplant related complications we investigated the pre-transplantation metabolic signature to assess the possibility of pre-transplant risk stratification. This pilot study was composed of 14 patients undergoing myeloablative conditioning followed by either HLA matched related, 
Introduction
Transplantation of hematopoietic progenitors from an HLA matched donor is a curative procedure for many patients with hematologic malignancies and disorder of hematopoiesis. Graft vs. host disease (GVHD) is a frequently observed complication of stem cell transplantation (SCT) which contributes to transplant related mortality and adversely impacts clinical outcomes following transplantation. GVHD after allogeneic HSCT is a reaction of donor immune cells to recipient tissues. An inflammatory cascade triggered by the preparative regimen causes activated donor T cells to damage epithelial cells. About 35%-50% of HSCT recipients will develop acute GVHD. It is mediated by donor-derived T cells responding to minor histocompatibility antigens encountered in the recipient. The T cell encounter alloantigens, undergo activation, perform functions such as cytokine secretion (IL-2, IL-4, IL-10, IL-12, IL-17 and interferon gamma by helper T cell subsets) and target lysis (granzyme and perforin secretion by cytotoxic T cells).
These functions are accompanied by significant metabolic adaptations in the T cells, including increased glycolysis and oxygen consumption as well as cytokine production mentioned earlier . T effector cells have been shown to increase their reliance on fatty acid metabolism during GVHD as well 10, 11 , for example, Prostaglandin E2 (PGE 2 ) has been implicated in modulating T cell effects of mesenchymal stromal cells on T cell populations 12 and PGE 2 priming of T cells reduces GVHD when localized to the site of alloreactivity 13 . Further, bone marrow stromal cells also exert an ameliorating influence on GVHD through indoleamine 2,3-dioxygenase (IDO) and PGE 2 expression 14 . These lipid mediated effects have been targeted in the treatment of GVHD, for instance, the effectiveness of leukotriene inhibitor monteleukast has long been recognized in managing GVHD of the lung 15, 16 . Additionally, prostaglandins have been studied in GVHD prevention strategies 17 , particularly PGE 2 13 . A leukotriene inhibitor, eicosapentanoic acid (EPA) has also been studied in the treatment of GVHD as well as prophylaxis 18, 19 . Prostaglandin mediators FT1050 (16, and FT4145
(dexamethasone) are also being studied in clinical trials of GVHD prophylaxis using ex-vivo modification of the allograft 20, 21 . These observations make it crucial to gain an understanding regarding the lipid and metabolic changes that come about following dose intensive, myeloablative conditioning, and how the metabolome and the lipidome might impact T cell function following SCT. Modern methods of lipidomics and metabolomics allows us to study such changes in detail [22] [23] [24] [25] [26] .
Recent studies have demonstrated that a dynamical systems model of T cell reconstitution may allow understanding alloreactivity in terms of antigenic differences between donors and recipients and ensuing T cell responses [27] [28] [29] . This model incorporates the idea that when T cells become activated and undergo metabolic changes upon antigen encounter, they may increase mass, and this appears to be the case when T cell masses are measured following allogeneic SCT 30 . This change in mass is likely driven by the cytokine and chemokine milieu in these patients, which is likely to be altered because of conditioning chemotherapy and radiation induced tissue damage. Further chemokine release is mediated by the effects of inflammation due to infections and endothelial injury. These changes in the post-transplant milieu may be investigated through the study of the metabolomic and lipidomic profile. In this paper we describe the lipidomic and metabolomic profiles of patients undergoing myeloablative conditioning and stem cell transplantation obtained prior to the infusion of stem cell graft and potential towards risk stratification with respect to the development of the GVHD.
Materials and Methods

Patients
Patients were enrolled prospectively in a Virginia Commonwealth University (VCU)
Institutional Review Board (IRB)-approved observational study; patients provided written informed consent prior to enrollment. Patients underwent myeloablative conditioning followed by either HLA matched related (MRD), unrelated donor (URD), or autologous stem cell transplantation (auto). Conditioning regimens utilized included busulfan/cyclophosphamide (5), busulfan or melphalan with fludarabine (3 & 2 respectively), carmustine, etoposide, cytarabine and melphalan (3), total body irradiation and cyclophosphamide, melphalan (1 each). HLA matching was at the allelic level; allogeneic HCT recipients received ATG, calcineurin inhibitors and cellcept or methotrexate for GVHD prophylaxis. Blood samples were drawn prior to transplant, and on days 0, 14, 30, and 60 post-SCT. Blood was processed for plasma collection and frozen at -80°C until mass spectroscopy based metabolomic and lipidomic analysis. Given the small patient cohort, acute and chronic GVHD data were pooled, Glucksberg and NIH Consensus criteria were used to diagnose and stage GVHD.
Lipid and metabolite extraction for LC-MS/MS analyses
Blood plasma lipids extraction was carried out using a biphasic solvent system of cold methanol, methyl tertiary butyl ether (MTBE), and water with some modifications (Matyash et al. 2008) . In to a 20 µL blood plasma aliquot in a 1.5 mL polypropylene tube, and then vortexed. Next, 750 µL of cold MTBE was added, followed by vortexing and shaking with an orbital mixer. Phase separation was induced by adding 188 µL of MS-grade water. Upon vortexing (20 s) the sample was centrifuged at 12,300 rpm for 2 min. The upper organic phase was collected in two 300 µL aliquots and evaporated with a vapor trap. Dried extracts were resuspended using 110 µL of a methanol/toluene (9:1, v/v) mixture containing CUDA (50 ng/ml; internal standard for quality control of injection) with support of vortexing (10 s), and centrifuged at 800 rpm for 5 min, followed by transferring 100 uL of the supernatant into autosampler vial with an insert. The lower polar layer was collected and an aliquot of 125 µL was evaporated to dryness in a SpeedVac and resuspended in acetonitrile for polar metabolite analysis via HILIC LC-MS/MS method.
Metabolomics:GC-MS metabolite extraction
30μl of plasma sample was added to a 1.0 mL of pre-chilled (-20°C) extraction solution composed of acetonitrile, isopropanol and water (3:3:2, v/v/v). Sample were vortexed and shaken for 5 min at 4°C using the Orbital Mixing Chilling/Heating Plate. Next, the mixture was centrifuged for 2min at 14000 rcf. 450μL of the supernatant was dried with cold trap concentrator. The dried aliquot was then reconstituted with 450 μ L acetonitrile:water (50:50) solution and centrifuged for 2 min at 14000 rcf. The supernatant was transferred to a polypropylene tube and subjected to drying in a cold trap. The process of derivatization began with addition of 10 μ L of 40 mg/mL Methoxyamine hydrochloride solution to each dried sample and standard. Samples were shaken at maximum speed at 30 o C for 1.5 hours. Then, 91 μ L of MSTFA + FAME mixture was added to each sample and standard and capped immediately.
After shaking at maximum speed at 37 o C, the content was transferred to glass vials with microserts inserted and capped immediately.
Lipids: LC-MC/MC conditions
Untargeted lipid analysis was undertaken with Sciex TripleTOF 6600 coupled to Agilent 1290 LC. Lipids were separated on an Acquity UPLC CSH C18 column (100 × 2.1 mm; 1.7 µm) (Waters, Milford, MA, USA). The column was maintained at 65 °C and the flow-rate of 0.6 mL/min. The mobile phases consisted of (A) 60:40 (v/v) acetonitrile:water with 10 mM ammonium acetate and (B) 90:10 (v/v) isopropanol:acetonitrile with 10 mM ammonium acetate. The separation was conducted following a stepwise gradient: 0-2 min 15-30% (B), 2-2.5 min 48% (B), 2.5-11 min 82% (B), 11-11.5 min 99% (B), 11.5-12 min 99% (B), 12-12.1 15% (B), 12-14 min 15% (B). Negative and positive electrospray ionization (ESI) modes were applied with nitrogen serving as the desolvation gas and the collision gas. The parameters for detection of lipids were as follows: Curtain Gas: 35; CAD: High; Ion Spray Voltage: 4500 V; Source Temperature: 350°C; Gas 1: 60; Gas 2: 60; Declustering Potential: +/-80V, and collision energies +/-10.
Metabolites HILIC: LC-MS/MS conditions
Detection of water soluble plasma metabolites was carried out on Sciex TripleTOF 6600 coupled to Agilent 1290 LC. Analytes were separated on an Acquity UPLC BEH Amide Column, 130Å, 1.7 µm, 2.1 mm X 150 mm (Waters, Milford, MA, USA). The column was maintained at 45°C
and the flow-rate of 0.4 mL/min. The mobile phases consisted of (A) water with 10 mM ammonium formate, 0.125% formic acid, and (B) acetonitrile:water 90:10 (v/v) with 10 mM ammonium formate, 0.125% formic acid. The analytes separation was conducted following a stepwise gradient: 0-2 min 100% (B), 2-7.7 min 70% (B), 7.7-9.5 min 40% (B), and 9.5-10.25 min 30% (B), and 410.25-12.75 min 100% (B), 12. 75-16.75 100% (B) . A sample volume of 1 µL and 3 µL were injected for positive and negative mode, respectively. Negative and positive electrospray ionization (ESI) modes were applied with nitrogen serving as the desolvation gas and the collision gas. The parameters for detection of lipids were as follows: Curtain Gas: 35;
CAD: High; Ion Spray Voltage: 4500 V; Source Temperature: 300°C; Gas 1: 60; Gas 2: 60;
Declustering Potential: +/-80V, and collision energies +/-10.
Metabolites: GC-MS conditions
A Leco Pegasus IV time of flight mass spectrometer coupled with Agilent 6890 GC equipped with a Gerstel automatic liner exchange system (ALEX) that included a multipurpose sample (MPS2) dual rail, and a Gerstel CIS cold injection system (Gerstel, Muehlheim, Germany) was used to complement HILIC metabolite analysis. The transfer line was maintained at 280 °C.
Chromatography separation was achieved on a 30 m long, 0.25 mm i.d. Rtx-5Sil MS column (0.25 μ m 95% dimethyl 5% diphenyl polysiloxane film) with the addition of a 10 m integrated guard column was used (Restek, Bellefonte PA) with helium (99.999%; Airgas, Radnor, PA, U.S.A.) at a constant flow of 1 mL/min. The oven temperature was held constant at 50°C for 1 min and then ramped at 20°C/min to 330°C at which it is held constant for 5 min. The GC temperature program was set as follows: 50°C to 275°C final temperature at a rate of 12 °C/s and hold for 3 minutes. The injection volume was 1 μ L in splitless mode at 250 °C. Electron impact ionization at 70V was employed with an ion source temperature of 250°C. The scan mass ranged from 85 to 500 Da with acquisition rate of 17 spectra/second.
Statistical analysis
Prior to statistical analysis, metabolomic and lipidomic data were subjected to preprocessing as follows. Data was first normalized by a variant of a 'vector normalization' by calculating the sum of all peak heights for all identified metabolites for each sample and thereafter normalizing each compound by the total average of the sum. Multivariate statistical analysis tends to focus on metabolites with high intensities. To avoid this tendency, log scaling was applied to reduce the effect of large peaks and scale the data into a more normally distributed pattern. Pareto scaling, which uses the square root of the standard deviation as the scaling to change the emphasis from metabolites with high concentrations to those with moderate or small abundances, was also used for analyzing parameters with large variation.
Patient cohort was divided into patients that developed either acute or chronic GVHD and patients that did not develop GVHD. Since the analysis was performed before transplantation, autologous stem cell transplant patients that did not develop GVHD were grouped with allograft recipients that also did not develop GVHD. Partial Least Squares Discriminant Analysis (PLS-DA) was used to create a bilinear model to fit the data (Figure 1 ). Multivariate statistical methods as PLS-DA have been introduced to reduce the complexity of metabolic spectra and help identify meaningful patterns in high-resolution mass spectrometric data. In this method, the PLS-DA scores can be filtered through calculation of the variable importance in projection (VIP) and used to estimate the contribution of lipids and metabolites for class separation. Univariate AUCROC analyses was used to find potential biomarkers with sufficient power to separate the groups (Figure 1 ). The result shows the t-test p-value, the AUCROC value with the confidence interval computed using 500 bootstrap replications. The criteria to choose the stronger potential biomarkers for GVHD was to select compounds with the highest AUCROC performance and lowest p-value (p<0.05). The calculated optimal cutoff was used to estimate the associated sensitivity and specificity values. Positive and negative likelihood ratios are calculated from the sensitivity and specificity output. The data was analyzed using MetaboAnalyst 3.5 maintained by Xia Lab at McGill University.
Results
A total of 14 patients were accrued in this study (Table 1) . Of these, 10 underwent a myeloablative allograft and 4 underwent an autologous SCT. Cohort was composed of 7 match related donors, 3 unrelated donors, and 4 autologous stem cell transplant recipients, with mean age of 50 (±10) years old, 57% women and 43% male, and 11 Caucasians and 3 African Americans.
Following preprocessing and filtering to remove low quality data, in the individual patient data sets, the final aggregate, analyzable data set consisted of 225 plasma lipids and 139 non lipid small molecule metabolites derived from the patients. The statistical approach used for data analysis ( Figure 1 ) was designed to provide meaningful and validated results optimized for the small sample size of the cohort, aiming to find potential biomarkers of GVHD to support future The more important variables for class separation suggest metabolic pathway tendencies enabling pre-transplant prediction of onset of GVHD So far, our study has identified 20 metabolites whose differential presence corelates strongly with the eventual onset of GVHD suggesting an inherent metabolic disturbance that predispose a patient towards GVHD as early as the day of SCT. Further examination of these metabolites indicates that they modulate three related metabolic pathways. Activated phospholipids metabolism appears to be one of the main alterations predicting GVHD pre-transplant. 1-monopalmitin is a monoacylglycerol that had a high VIP score (2.54), and its elevation in GVHD group indicates a metabolic shift in its direction, with phospholipid degradation in cell membranes to produce diacylglycerol, the precursor for MAGs. Alternatively, the no-GVHD state appears to be associated with elevation of monounsaturated and polyunsaturated fatty acids ( Figure 3A ). Hexose, more commonly called glucose had also a high VIP score (2.67),
indicating that elevated glucose uptake is on demand for energy production in the Tricarboxilic Acid Cycle (TCA), as well as increased aerobic glycolysis required for hematopoietic cell proliferation. These process increase the production of NADH used in the electron transport chain, but its upregulation induces excessive reducing power that triggers processes such as fatty acid unsaturation and ROS production ( Figure 3B ). The levels of oxidative stress originated by excessive ROS production is controled by the glutathione metabolism, where NADH is also used to reduce glutathione for its antioxidant action over ROS. The excessive demand for antioxidative process can deplete glutathione and its precursor cysteine, increasing the demand of 2-aminobutyric acid that can either modulate the glutathione synthesis or be used in ophtalmate synthesis, a tripeptide analog of glutathione, with similar compensative antioxidative actions ( Figure 3C ).
The more important variables for class separation can be used to build models for GVHD prediction pre-transplant
To evaluate the potential to build models predicting future GVHD the top 20 highest VIP scores were used in an exploratory analysis based in multivariate Receiver Operating Characteristic Univariate ROC curve analysis finds potential biomarkers of GVHD with plasmatic data pretransplant.
To find biomarkers of GVHD among the top 20 predictors selected in the PLS-DA method, a univariate ROC curve analysis was performed for each of the top 20 variables on day of transplant. The optimal cutoff found for each predictor from the ROC curve was used to estimate the sensitivity and specificity, and to calculate the positive and negative likelihood ratios.
The 5 best biomarkers and their respective estimates are depicted in Table 3 , and the comparison plot for each potential biomarker is presented in Figure 5 where presence of outliers is of notice.
These data support the previous finding that a model with 5 metabolic biomarkers may provide a robust model for GVHD prediction.
All potential biomarkers, shows high sensitivity and specificity, except for FA 20:1 that, while it has maximum sensitivity, has low specificity. The positive likelihood ratio of 1-monopalmitin and DG (38:5) and DG (38:6) shows that a patient with a positive test result for these biomarkers will have very high odds of developing GVHD. 1-monopalmitin, 2-aminobutyric acid, and DG 38:5 showed CI ranging inside an acceptable AUROC values (0.6 -1.0). Yet, the bootstrap confidence interval for DG 36:6 and FA 20:1 are indicative that these two compounds must be taken with caution despite their high sensitivity estimate.
The evaluation of SVM model performance analyzed by AUROC shows the 5 specific biomarkers model is accurate in predicting the future development of GVHD (AUC=0.995) with patient's plasma pre-transplant ( Figure 6A ). The predictive power of class probability of the SVM method was also tested and the confusion matrix represented by the probability plot in Figure 6B shows the method is robust without any misclassification.
Discussion
The identification of biomarkers that better enable the risk stratification of SCT patients with respect to the potential for development of GVHD has significant clinical utility in the execution of BMT protocols. Such a capability enables the development of new treatments and disease detection and enable evidence based treatments 32, 33 . The strategy used in our study to enable this goal investigated the plasma metabolome and lipidome to profile SCT patients. This approach resulted in the generation of complex and multidimensional data that required the use of multivariate statistical approaches to decrease dimensional space, a common approach in The discovery of top 20 lipids and metabolites separating the GVHD from no-GVHD patients identify the main metabolic pathways involved in the phenotype of patients. As an example, 2-aminobutyric acid was identified as a significant biomarker and is a byproduct in the cysteine biosynthesis pathway and relates to glutathione (GSH) metabolism. Soga et al. 38 reported plasma and liver depletion of GSH in acetaminophen poisoning and concomitant increases of ophthalmate. Ophtalmate is a tripeptide (glutamate/2-aminobutyrate/glycine), also known as ophthalmic acid. It is an analog of GSH in which the cysteine group is replaced by L-2-aminobutyrate. It has been proposed that oxidative stress leads to intracellular depletion of GSH, depletion of cysteine, and consequent activation of ophthalmate synthesis. GSH is the predominant low-molecular-weight thiol in animal cells effectively scavenging free radicals.
Moreover, its cellular concentration are reduced in response to protein malnutrition, oxidative stress, and many pathological conditions 39, 40 . These are all conditions prevalent following myeloablative chemotherapy and radiation therapy. 2-aminobutiric acid also increases intracellular GSH levels by regulation of AMP-activated protein kinase and increase of NADPH and reduction of GSH. Plasma levels of cysteine is also regulated by oxidative stress and that supply of cysteine is directly related to GSH synthesis 41 . We found that cysteine levels are slightly elevated in the GVHD group, although the difference compared with no-GVHD is not statistically significant (p=0.07). This find indicates that pre-transplant the GVHD group profile favors the ophthalmate pathway to compensate for oxidative stress. oxidative phosphorylation, the process is triggered and is vital for T cells effector functions, as cytokine production 48 . Therefore, high energy demand in the proliferative phase leads to increased glucose uptake and accelerated glucose metabolism, enhance aerobic glycolysis besides oxidative phosphorylation. Patients that will eventually develop GVHD appear to demonstrate this metabolic profile on the day of stem cell, and donor T cell infusion.
Another aspect of the metabolic profile of GVHD-prone patients is that lipid metabolism is significantly altered, placing lipids as the main biomarkers to predict GVHD. Lipid modulation is expected due to metabolic demands of compromised hematopoietic tissue, immunologic response and underlined inflammatory profile of the patients related to the conditioning regimen.
Of the important plasma biomarkers of GVHD, free fatty acids found in our study are 
Conclusion
Our study demonstrates that the pre-transplant lipidome and the metabolome of SCT recipients has significant potential towards their risk stratification with respect to the development of the GVHD indicating potential use as biomarkers for this purpose. The identified potential biomarkers indicate a pro-inflammatory metabolic profile in patients that will eventually develop GVHD. The role of GSH and its association with 2-aminobutyric acid, coupled with signs of altered glucose metabolism, support the hypothesis that in patients that will develop GVHD, 
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